A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy

NCT00559962 Phase 2 COMPLETED Results posted

To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

Details

Lead sponsor	Aegerion Pharmaceuticals, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	260
Start date	2007-10
Completion	2008-11

Conditions

• Hyperlipidemia

Interventions

• AEGR-733
• placebo
• AEGR-733
• AEGR-733
• AEGR-733
• AEGR-733 and atorvastatin
• AEGR-733 and fenofibrate
• AEGR-733 and ezetimibe

Primary outcomes

• Absolute Change From Baseline in Percent Hepatic Fat — Baseline and 12 weeks on study drug
  Absolute change from Baseline in percent hepatic fat

Countries

United States